癌におけるKeap1/Nrf2軸の標的化:分子メカニズムと薬理学的介入

Yangchen Xia¹, Ziyang Xu¹, Xun Yuan²

¹Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Investigational new drugs

|September 5, 2025

まとめ

核因子エリソイド2関連因子2 (Nrf2) は,保護経路を調節しますが,がんを促進します. Nrf2を阻害することは,特に炎症に関連した癌の治療戦略の可能性がある.

科学分野:

分子生物学
癌研究
薬理学について

背景:

核因子エリソイド2関連因子2 (Nrf2) は,炎症と酸化還元バランスを含む細胞保護機構の重要な調節因子である.
新興の証拠は,Nrf2経路が腫瘍細胞の生存と悪性変異を促進することを示唆している.
Nrf2の二重な役割は,標的の治療介入についてより深い理解を必要とします.

研究の目的:

癌の病原性におけるNrf2の分子機構と生物学的機能を明らかにする.
癌治療におけるNrf2活性に対する薬理学的抑制における最近の進歩をレビューする.
Nrf2経路を標的とした新しい化学化合物と臨床試験の進展について議論する.

主な方法:

Nrf2を調節する分子メカニズムに関する文献レビュー
癌の生物学と進行における Nrf2 の役割の分析
癌治療におけるNrf2阻害剤に関する臨床前および臨床試験のレビュー

主要な成果:

Nrf2の制御ネットワークとその癌促進機能の詳細な説明
Nrf2の活動を阻害するために設計された様々な化学分子の特定.
癌研究におけるNrf2標的治療の現状の概要

結論:

Nrf2の薬理学的抑制は,酸化ストレスと炎症に関連した癌の治療に有望な可能性を示しています.
Nrf2を標的にすると,がん細胞の生存メカニズムが乱され,腫瘍の進行が妨げられます.
Nrf2を標的とするがん治療の最適化には,さらなる研究と臨床評価が不可欠です.

キーワード:

抗酸化経路癌についてキープ1 Nrf2 について

さらに関連する動画

07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

関連する概念動画

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:46

Electron Transport Chain: Complex I and II

15.0K

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

15.0K

02:38

Mitogens and the Cell Cycle

6.6K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

6.6K

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

5.1K

01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.8K

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

2.8K

02:34

Inhibition of Cdk Activity

4.9K

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...